Also Known As
4q12 (CHIC2) deletion
PDGFRA-FIP1L1 gene rearrangement
FIP1-like-1/platelet-derived growth factor alpha
Formal Name
This article was last reviewed on
This article waslast modified on November 22, 2019.
At a Glance
Why Get Tested?

To help investigate the cause of hypereosinophilia (HE), a condition with persistent increase in the number of eosinophils, a specific type of white blood cell, or hypereosinophilic syndrome (HES), which is HE with associated tissue or organ damage; to help determine if someone with HE or HES can be treated with a tyrosine kinase inhibitor (TKI) such as imatinib

When To Get Tested?

After complete blood counts (CBC) indicate that you have persistently elevated eosinophils and your healthcare practitioner has ruled out other causes such as allergies, parasitic infection, or medication; at regular intervals when you are being treated for HE or HES with imatinib

Sample Required?

A blood sample drawn from a vein in your arm or a bone marrow sample collected using a bone marrow aspiration and/or biopsy procedure

Test Preparation Needed?


You may be able to find your test results on your laboratory's website or patient portal. However, you are currently at Lab Tests Online. You may have been directed here by your lab's website in order to provide you with background information about the test(s) you had performed. You will need to return to your lab's website or portal, or contact your healthcare practitioner in order to obtain your test results.

Lab Tests Online is an award-winning patient education website offering information on laboratory tests. The content on the site, which has been reviewed by laboratory scientists and other medical professionals, provides general explanations of what results might mean for each test listed on the site, such as what a high or low value might suggest to your healthcare practitioner about your health or medical condition.

The reference ranges for your tests can be found on your laboratory report. They are typically found to the right of your results.

If you do not have your lab report, consult your healthcare provider or the laboratory that performed the test(s) to obtain the reference range.

Laboratory test results are not meaningful by themselves. Their meaning comes from comparison to reference ranges. Reference ranges are the values expected for a healthy person. They are sometimes called "normal" values. By comparing your test results with reference values, you and your healthcare provider can see if any of your test results fall outside the range of expected values. Values that are outside expected ranges can provide clues to help identify possible conditions or diseases.

While accuracy of laboratory testing has significantly evolved over the past few decades, some lab-to-lab variability can occur due to differences in testing equipment, chemical reagents, and techniques. This is a reason why so few reference ranges are provided on this site. It is important to know that you must use the range supplied by the laboratory that performed your test to evaluate whether your results are "within normal limits."

For more information, please read the article Reference Ranges and What They Mean.

What is being tested?

FIP1L1-PDGFRA is an abnormal fusion gene sequence that causes excessive growth of eosinophils, a type of white blood cell. It is a rare cause of hypereosinophilia (HE) and hypereosinophilic syndrome (HES). This test detects the FIP1L1-PDGFRA gene sequence.

While some genetic abnormalities are inherited from our parents, they can also come from changes that occur to genes or chromosomes after a person is born. These are called somatic mutations, which can occur through exposure to various environmental factors (e.g., radiation, certain chemicals), but more often for unknown reasons.

The FIP1LI-PDGFRA gene sequence is one of those genetic changes acquired after birth. It occurs when a mutation on chromosome 4 causes deletion of approximately 800 nucleotides, or DNA building blocks, which normally separate the FIP1L1 and PDGFRA genes. Because of this deletion, the two genes are brought together, producing a new fusion gene. Other types of mutations can also lead to abnormalities of the PDGFRA gene, but this deletion is the most common.

Normally, the PDGFRA gene provides instructions for making a protein that controls processes like cell growth and division. When the mutation occurs and the FIP1L1-PDGFRA fusion gene is present, the gene sequence still provides instructions for making that protein, but the protein that results is different because it is always activated and continues to send signals for growth and division. With constant signals for growth, eosinophils (and sometimes other blood cells) can grow out of control, causing hypereosinophilia (HE) and hypereosinophilic syndrome (HES), which can be fatal if not treated promptly.

Hypereosinophilia (HE) and Hypereosinophilic syndrome (HES)

Eosinophils are a type of white blood cell that are involved in allergic reactions and immune responses to certain parasites. The number of eosinophils in the blood may be elevated with these conditions. Hypereosinophilia is the prolonged overproduction of eosinophils. As increasing numbers of eosinophils infiltrate and inflame tissues, HES develops. HES is a condition caused when infiltrative eosinophils affect and damage a variety of organs, including the heart, lungs and the nervous system.

Common symptoms include chest pain and shortness of breath, if the heart is involved. People with HES may also have anemia or excessive clotting (hypercoaguability), stroke, blurred vision or slurred speech. Other symptoms may involve the gastrointestinal system or the skin. Sometimes, there may be no symptoms, when tissue or organ damage is less severe.

There are a number of causes of HE and HES besides genetic abnormalities. Allergic diseases are the most common cause in the developed world. Parasitic diseases, certain cancers, autoimmune disorders, skin disease, inflammatory bowel syndrome, and Addison disease can also cause HES. If an individual has HES and a health practitioner has ruled out these secondary causes, genetic testing can determine if FIP1L1-PDGFRA or other genetic abnormality is the underlying cause.

Only 0.4% of people with persistently high numbers of eosinophils carry the FIP1L1-PDGFRA gene. It is most common in individuals between 20 and 50 years old. Although it is a rare cause of HE and HES, it is important to identify it because HE/HES with FIP1L1-PDGFRA can be fatal if not treated but is effectively treated with the drug imatinib.

How is the sample collected for testing?

A blood sample is obtained by inserting a needle into a vein in the arm or a bone marrow sample is collected using a bone marrow aspiration and/or biopsy procedure.

Is any test preparation needed to ensure the quality of the sample?

No test preparation is needed.

Accordion Title
Common Questions
  • How is it used?

    This test is used to detect the genetic mutation FIP1L1-PDGFRA. FIP1L1-PDGFRA is an abnormal gene sequence that causes excessive growth of eosinophils, a type of white blood cell.

    Eosinophils are part of the body's immune response and can be elevated in the blood with different diseases and conditions. Some common examples are allergic responses and parasitic infections. A complete blood count (CBC) is a test that may show increased numbers of eosinophils in the blood (hypereosinophilia) with these conditions.

    The FIP1L1-PDGFRA gene sequence is a rare cause of increased eosinophils. Testing for the mutation may be used to help determine the cause of a persistently elevated number of eosinophils, as determined by a CBC, after other tests have ruled out more common secondary causes. These other tests may include, for example, allergy blood tests or stool tests for parasites. (See Common Questions for more on these.)

    FIP1L1-PDGFRA testing may be used to:

    • Help diagnose the cause of hypereosinophilia (HE) and hypereosinophilic syndrome (HES), a type of bone marrow disorder
    • Help determine HE/HES prognosis and responsiveness to therapy with a tyrosine kinase inhibitor (TKI); people with FIP1L1-PDGFRA respond well to treatment with a TKI called imatinib.

    See Common Questions for more details on test methods.

    Tests for FIP1L1-PDGFRA may be performed along with other genetic tests for less common mutations related to eosinophilia. It may also be performed along with:

    • Chromosme analysis – to detect other genetic abnormalities that may be the cause of HE/HES, such as PDGFRB or FGFR1 rearrangement
    • BCR-ABL1 – if chronic myelogenous leukemia (CML) is suspected and thus needs to be ruled out
    • KIT mutation – to rule out mutation in the KIT gene; people with KIT D816 mutation (mastocytosis) do not respond to imatinib treatment.
    • Interleukin-5 – may be tested because, if elevated, it suggests clonal T-cell disease when found with HES
    • Immunoglobulin E (IgE) level – people with elevated IgE levels may have a lower risk of developing hypereosinophilic syndrome-associated cardiovascular disease and may respond well to steroid therapy.
    • An initial evaluation of HES may include cardiac tests to look for evidence of organ damage from the condition and a troponin test to make sure imatinib won't cause cardiac shock.
  • When is it ordered?

    FIP1L1-PDGFRA testing is ordered when CBCs indicate that someone has persistently elevated numbers of eosinophils and other causes like allergies, asthma, parasitic infections, adrenal insufficiency, and lymphoma have been ruled out.

    Testing may be ordered after an abnormal eosinophil count when HES is suspected due to a person's signs and symptoms. HES and leukemias (either acute or chronic) may have similar presentations, but sometimes there are no early symptoms and the conditions are found only through a routine CBC.

    Examples of common HES signs and symptoms include:

    • Fever
    • Fatigue
    • Cough, wheezing, shortness of breath
    • Swelling under the skin around the eyes and lips, in the throat, or on the hands and feet
    • Swollen lymph nodes or organs
    • Muscle pain
    • Itching, rash or blistering of the skin
    • Diarrhea
  • What does the test result mean?

    The result of the test may be reported as "positive" (the gene sequence is present) or as "negative" (the gene sequence is not present).

    If a person has abnormally high numbers of eosinophils and tests positive for the FIP1L1-PDGFRA fusion gene, then the fusion gene is confirmed as the underlying cause of that person's hypereosinophilia (HE) or hypereosinophilic syndrome (HES).

    Note that HE/HES with FIP1L1-PDGFRA may be diagnosed as acute or chronic leukemia, a myeloproliferative or myelodysplastic disorder, or even systemic mastocytosis, based on the World Health Organization's 2008 diagnostic guidelines. Regardless the diagnosis, individuals with the FIP1L1-PDGFRA fusion gene respond very well to treatment with the tyrosine kinase inhibitor imatinib.

    If a person tests negative for FIP1L1-PDGFRA, depending on other test results, the person may have another type of myeloproliferative or myelodysplastic neoplasm or may be diagnosed with HES without a specific cause (idiopathic). FIP1L1-PDGFRA-negative cases of HES do not respond as well to imatinib except for rare cases with PDGFRB rearrangement (see below).

  • Is there anything else I should know?

    Sometimes people develop resistance to imatinib even though the tyrosine kinase inhibitor is usually very effective for treating people with the FIP1L1-PDGFRA fusion gene at low doses. For the rare individuals whose HES is resistant to imatinib, stem cell transplants have reversed the organ dysfunction caused by hypereosinophilia. However, health practitioners have limited experience with this treatment, so it is not used routinely. Chemotherapy has also been used with some success for people with the fusion gene who don't respond to treatment with imatinib. Some individuals with the fusion gene are also treated with corticosteroids to lower their eosinophil count and help control organ damage.

    People with FIP1L1-PDGFRA may also manifest as acute myeloid or lymphoblastic leukemia, though that is rare. FIP1L1-PDGRA has also been found infrequently in other leukemias and successfully treated with imatinib.

    Unlike some other genetic abnormalities, FIP1L1-PDGFRA related change is very subtle and thus cannot be detected with routine karyotyping, which involves looking at chromosomes under a microscope.

  • If I have the FIP1L1-PDGFRA fusion gene, should my family members be tested?

    No. The chromosome deletion that leads to the FIP1L1-PDGFRA fusion is what is known as somatic. It is a mutation acquired during a person's lifetime and cannot be inherited.

  • Should everyone with leukemia be tested?

    Testing is only indicated when you have an elevated number of eosinophils (hypereosinophilia, HE) and your health practitioner needs to find the cause. The majority of people with leukemia do not have the FIP1L1-PDGFRA fusion gene.

  • Are there other genetic abnormalities associated with neoplastic hypereosinophilia or hypereosinophilic syndrome (HE/HES)?

    Yes, while the FIP1L1-PDGFRA fusion gene is the most common, there are other mutations that can cause malignant disorders associated with eosinophilia. They include abnormalities of the genes FDGFRB or FGFR1. Similar to PDGFRA, those mutations lead to excess production of the enzyme tyrosine kinase, which is responsible for overactive cell growth. As with FIP1L1-PDGFRA, people with FDGFRB abnormalities respond well to treatment with a tyrosine kinase inhibitor, while those with FGFR1 generally do not. Tests for less common genetic abnormalities associated with eosinophilia may be done as part of a panel for myeloproliferative disorders or eosinophilia or may be ordered separately based on the judgment of the health practitioner.

  • What other tests may be done to rule out secondary causes of eosinophilia?

    Before testing for genetic causes of hypereosiniophilia, your health practitioner will rule out more common causes like allergies, asthma, medication, or parasites and other secondary causes like T-cell lymphoma, Hodgkin lymphoma, other myeloproliferative neoplasms, and leukemias. Since allergic diseases are the most common cause of hypereosinophilia in the developed world, you will likely be given allergy blood tests. Especially if you have been traveling, your stool may be tested for parasites with an ova and parasites exam. Depending on your symptoms, further blood tests may be done to look for other abnormalities like elevated serum vitamin B12, which would indicate a myeloproliferative disorder and possibly lead to a bone marrow biopsy.

  • What are some types of lab methods used for this testing?

    Different types of tests may be ordered to detect FIP1L1-PDGFRA. Samples may be analyzed using fluorescence in situ hybridization (FISH) or reverse transcription-polymerase chain reaction (RT-PCR). The FISH method uses fluorescent dye-labeled probes to detect the deletion of the portion of DNA (4q12, CHIC2 region) that results in the abnormal gene sequence, whereas the RT-PCR method directly detects the FIP1L1-PDGFRA gene sequence when it is present.

View Sources

Loules, G. et al. (2009 February 2). FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia. BMC Blood Disorders. 2009; 9(1). doi:10.1186/1471-2326-9-1. Available online at through Accessed August 2014.

(2014 June 17). Chronic Eosinophilic Leukemia. National Cancer Institute. Available online at through Accessed August 2014.

(Reviewed 2012 February). FIP1L1. Genetics Home Reference. Available online at through Accessed August 2014.

(Reviewed 2012 March). PDGFRA-associated chronic eosinophilic leukemia. Genetics Home Reference. Available online at through Accessed August 2014.

(August 2014). Eosinophilia Panel by FISH. ARUP Laboratories. Available online at through Accessed August 2014.

Bain, B. (2010 May). Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Haematologica. 2010; 95(5): 696–698. doi: 10.3324/haematol.2009.021675. Available online at through Accessed August 2014.

Michaelann, L. et al. (Updated 2013 May 29). Eosinophilia. Medscape. Available online at through Accessed August 2014.

Samavedi,V. et al. (Updated 2014 September 8). Hypereosinophilic Syndrome. Medscape. Available online at through Accessed September 2014.

Vardiman, J. and Hyjek, E. (2011 December 10). World Health Organization Classification, Evaluation, and Genetics of the Myeloproliferative Neoplasm Variants. ASH Education Book 2011; 2011(1) 250-256. Available online at through doi: 10.1182/asheducation-2011.1.250. Accessed August 2014.

Shah, S. et al. (2014 March 27). Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia. Journal of Hematology & Oncology. 2014; 7(26). doi:10.1186/1756-8722-7-26. Available online at through Accessed August 2014.

Vardiman, et al. (2009 July 30). The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114 (5) DOI: Available online at through Accessed August 2014.

Abutalib, Syed A. and Markman, Maurie. (© 2014). Cancer Consult: Expertise for Clinical Practice. Google eBook Pp. 167-175. Accessed August 2014.

Krishnan, K. et al. (Updated 2014 April 29). Systemic Mastocytosis. Medscape. Available online at through Accessed August 2014.

(Reviewed 2013 July). Myeloproliferative Neoplasms Laboratory Support of Diagnosis and Management. Quest Diagnostics. Available online at through Accessed August 2014.

Liesveld, J. and Reagan, P (Reviewed 2014 January). Hypereosinophilic Syndrome. The Merck Manual. Available online through Accessed August 2014.

(Reviewed 2012 February). Chromosome 4. Genetics Home Reference. Available online at through Accessed August 2014.

© 2014. CHIC2, 4q12 Deletion (FIP1L1 and PDGFRA Fusion), FISH. Mayo Medical Laboratories. Available online at through Accessed August 2014.

(©2014) American Society of Clinical Oncology. Leukemia - Eosinophilic: Diagnosis. Available online at through Accessed September 2014.

Ask a Laboratory Scientist

This form enables patients to ask specific questions about lab tests. Your questions will be answered by a laboratory scientist as part of a voluntary service provided by one of our partners, American Society for Clinical Laboratory Science. Please allow 2-3 business days for an email response from one of the volunteers on the Consumer Information Response Team.

Thank you for using the Consumer Information Response Service ("the Service") to inquire about the meaning of your lab test results.  The Service is provided free of charge by the American Society for Clinical Laboratory Science, which is one of many laboratory organizations that supports Lab Tests Online.
Please note that information provided through this free Service is not intended to be medical advice and should not be relied on as such. Although the laboratory provides the largest single source of objective, scientific data on patient status, it is only one part of a complex biological picture of health or disease. As professional clinical laboratory scientists, our goal is to assist you in understanding the purpose of laboratory tests and the general meaning of your laboratory results. It is important that you communicate with your physician so that together you can integrate the pertinent information, such as age, ethnicity, health history, signs and symptoms, laboratory and other procedures (radiology, endoscopy, etc.), to determine your health status. The information provided through this Service is not intended to substitute for such consultations with your physician nor specific medical advice to your health condition.
By submitting your question to this Service, you agree to waive, release, and hold harmless the American Society for Clinical Laboratory Science and its affiliates or their past or present officers, directors, employees, agents, and Service volunteers (collectively referred to as "ASCLS") and the American Association  for Clinical Chemistry and its affiliates or their past or present officers, directors, employees, agents, and Service volunteers (collectively referred to as "AACC") from any legal claims, rights, or causes of action you may have in connection with the responses provided to the questions that you submit to the Service.
AACC, ASCLS and its Service volunteers disclaim any liability arising out of your use of this Service or for any adverse outcome from your use of the information provided by this Service for any reason, including but not limited to any misunderstanding or misinterpretation of the information provided through this Service.